Literature DB >> 2849092

Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.

P S Ganly1, C Arthur, J M Goldman, W E Schulenburg.   

Abstract

This report describes a patient with chronic granulocytic leukaemia who developed cataracts on busulphan treatment. Following allogeneic bone marrow transplantation, he developed cytomegalovirus retinitis, which was treated successfully with trisodium phosphonoformate (foscarnet). Cytomegalovirus retinitis and its therapy, and busulphan-induced cataract are discussed.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2849092      PMCID： PMC2428687          DOI： 10.1136/pgmj.64.751.389

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  12 in total

1.  Treatment of CMV retinitis in an AIDS patient.

Authors:  J F Acheson; S M Shah; D J Spalton; C Bradbeer; R N Thin
Journal:  Br J Ophthalmol       Date:  1987-11       Impact factor: 4.638

2.  Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease.

Authors:  J S Pepose; G N Holland; M S Nestor; A J Cochran; R Y Foos
Journal:  Ophthalmology       Date:  1985-04       Impact factor: 12.079

3.  Foscarnet for cytomegalovirus retinitis.

Authors:  D R Singer; T J Fallon; W E Schulenburg; G Williams; J Cohen
Journal:  Ann Intern Med       Date:  1985-12       Impact factor: 25.391

4.  9-(1,3-Dihydroxy-2-propoxymethyl)guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome.

Authors:  M C Bach; S P Bagwell; N P Knapp; K M Davis; P S Hedstrom
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

5.  Cataract after busulphan treatment.

Authors:  M P Ravindranathan; V J Paul; E T Kuriakose
Journal:  Br Med J       Date:  1972-01-22

6.  Lens changes in chronic granulocytic leukemia. Possible relationship to chemotherapy.

Authors:  S M Podos; G P Canellos
Journal:  Am J Ophthalmol       Date:  1969-09       Impact factor: 5.258

7.  Epidemiology of cytomegalovirus infection after transplantation and immunosuppression.

Authors:  M Fiala; J E Payne; T V Berne; T C Moore; W Henle; J Z Montgomerie; S N Chatterjee; L B Guze
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

8.  Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

9.  Cytomegalovirus retinitis in adults. A manifestation of disseminated viral infection.

Authors:  H W Murray; D L Knox; W R Green; R M Susel
Journal:  Am J Med       Date:  1977-10       Impact factor: 4.965

10.  Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine.

Authors:  D Felsenstein; D J D'Amico; M S Hirsch; D A Neumeyer; D M Cederberg; P de Miranda; R T Schooley
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391
View more
  6 in total

1.  Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.

Authors:  A M Taburet; C Katlama; C Blanshard; G Zorza; D Gazzard; E Dohin; B G Gazzard; C Frostegard; E Singlas
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Cytomegalovirus in hematopoietic stem cell transplant recipients.

Authors:  Per Ljungman; Morgan Hakki; Michael Boeckh
Journal:  Hematol Oncol Clin North Am       Date:  2011-02       Impact factor: 3.722

3.  Foscarnet 5 versus 7 days a week treatment for severe gastrointestinal CMV disease in HIV-infected patients.

Authors:  B Salzberger; A Stoehr; H Jablonowski; W Heise; U Ewald; K Peters; G Fätkenheuer; M Schrappe
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

4.  The human eye (retina): a site of persistent HCMV infection?

Authors:  Jens-Uwe Vogel; Corinna Fleckenstein; Mathias Wagner; Hermann O C Gümbel; Dirk Theegarten; Jindrich Cinatl; Hans Wilhelm Doerr
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-01-26       Impact factor: 3.117

Review 5.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

6.  CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins.

Authors:  Francesco Vassallo; Raffaele Nuzzi; Ilaria Cattani; Chiara Dellacasa; Luisa Giaccone; Francesco Giuseppe De Rosa; Rossana Cavallo; Giorgia Iovino; Lucia Brunello; Benedetto Bruno; Alessandro Busca
Journal:  Ther Adv Hematol       Date:  2020-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.